Dianthus Therapeutics
DNTH
97 hedge funds and large institutions have $366M invested in Dianthus Therapeutics in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 39 increasing their positions, 22 reducing their positions, and 9 closing their positions.
78% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 9
77% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 22
8% more funds holding
Funds holding: 90 → 97 (+7)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.55% less ownership
Funds ownership: 4.55% → 4% (-0.55%)
12% less capital invested
Capital invested by funds: $418M → $366M (-$52M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.8M |
| 2 |
O
OrbiMed
New York
|
+$12.5M |
| 3 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$2.12M |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
+$2.11M |
| 5 |
BlackRock
New York
|
+$2.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$7.31M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.18M |
| 3 |
ACM
Altium Capital Management
New York
|
-$1.95M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.4M |
| 5 |
Janus Henderson Group
London,
|
-$1.24M |
DNTH Hedge Fund Activity: Q2 2021 in Review
97 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q2 2021, worth a combined $366M — down 12% from $418M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new DNTH positions and 9 closed out — a net gain of 7 holders — while 39 added to existing stakes and 22 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $12.8M. The largest seller was Citadel Advisors, cutting an estimated $7.31M.
- 97 institutional investors held Dianthus Therapeutics (DNTH) as of Q2 2021, up from 90 in Q1 2021.
- Funds reported $366M of Dianthus Therapeutics stock for Q2 2021, down 12% quarter-over-quarter.
- 16 funds opened new Dianthus Therapeutics positions in Q2 2021 and 9 closed out, a net change of +7 holders.
- The largest Dianthus Therapeutics buyer in Q2 2021 was Great Point Partners, an estimated $12.8M added.
- The largest Dianthus Therapeutics seller in Q2 2021 was Citadel Advisors, an estimated $7.31M sold.
Based on aggregated 13F filings for Q2 2021.